Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Cabaletta Bio, Inc.NASDAQ: CABA

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $23.12M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 15.6% of total assets at the end of Q1 FY2026, up 15.6 pp from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.12M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Short-term debt amounts to 15.6% of total assets for CABA, versus a peer median of 1.2%.
CABA Competitors
Short-term Debt for CABA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CABACabaletta Bio, Inc.Mar 2026$23.12M USD——15.6%
EDITEditas Medicine, Inc.Mar 2026$14.2M USD——9.5%
LYELLyell Immunopharma, Inc.Mar 2026$9.36M USD——2.7%
ALLOAllogene Therapeutics, Inc.Mar 2026$8.42M USD——2.1%
CAPRCapricor Therapeutics, Inc.Mar 2026$7.18M USD+752.7%+74.5%2.2%
PRQRProQR Therapeutics N.V.Mar 2026€4.62M EUR-1.9%+21.1%4.7%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K USD——0.2%
IMMPImmutep LimitedDec 2025A$259.75K AUD-74.8%—0.2%
KYTXKyverna Therapeutics, Inc.Mar 2026$0 USD——0.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
HUMAHumacyte, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding CABA) —-1.9%+47.8%1.2%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.22M81.61M193.24M163.96M82.98M
Short-term Investments024.94M48.01M050.62M
Net Receivables00000
Inventory00000
Other Current Assets1.97M2.29M02.71M5.27M
Total Current Assets124.54M108.83M244.49M166.68M138.87M
Property, Plant & Equipment (Net)1.44M7.57M7.45M16.08M21.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets357K565K1.71M6.23M5.16M
Total Non-current Assets1.8M8.13M9.16M22.31M26.21M
Total Assets126.34M116.97M253.65M185.05M165.08M
Account Payables2.33M2.46M4.55M4.92M6.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.07M1.33M40K8.36M9.8M
Total Current Liabilities8.38M9.49M15.99M27.09M50.15M
Long-term Debt00002.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities02.96M1.46M5.63M2.88M
Total Liabilities8.38M12.45M17.45M32.71M53.03M
Common Stock0001K1K
Retained Earnings(112.59M)(165.56M)(233.24M)(349.1M)(516.96M)
Accumulated OCI0(47K)39K025K
Other Stockholders Equity00000
Minority Interest00000
Total Equity117.96M104.52M236.2M152.34M112.05M
Total Debt05.14M5.02M15.6M27.1M
Net Debt(122.22M)(76.47M)(188.22M)(148.36M)(55.88M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.